UBS O'Connor’s Bright Minds Biosciences DRUG Stock Holding History

UBS O'Connor’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,963	Closed	-$215K	–	406
2025 Q1	$215K	Buy	+5,963	New	+$218K	0.01%	247

Other funds holding DRUG

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS O'Connor's DRUG Position: Q2 2025 in Review

UBS O'Connor sold out of Bright Minds Biosciences (DRUG) in Q2 2025, closing a stake of 5,963 shares — an estimated $215K sold.

UBS O'Connor first reported a position in DRUG in Q1 2025 and held it in 1 quarter. The position peaked at $215K in Q1 2025. 47 funds tracked by Wall St. Rank hold DRUG as of Q2 2025.

UBS O'Connor reported no remaining Bright Minds Biosciences position as of Q2 2025 after selling out during the quarter.
UBS O'Connor sold 5,963 Bright Minds Biosciences shares in Q2 2025, an estimated $215K.
UBS O'Connor first reported a position in Bright Minds Biosciences in Q1 2025 and held it in 1 quarter.
UBS O'Connor's Bright Minds Biosciences position peaked at $215K in Q1 2025.
47 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.